Sleep apnea platform raises funding

BUFFALO, N.Y. – Ognomy, a telemedicine platform for sleep apnea care, has closed its series seed preferred financing round, now having raised more than $6.8 million since inception and surpassing 11,000 patients served. The financing, led by Impellent Ventures, with backing from a leading strategic partner in the sleep medicine industry, will be used to integrate additional AI-driven automation and information exchange into Ognomy’s platform. “We are thrilled to have the backing of Impellent Ventures and our new strategic partner,” said Dr. Daniel Rifkin, CEO of Ognomy. “This funding will allow us to accelerate our mission of providing accessible, high-quality care for sleep apnea patients across the country. With AI-driven automation and a fully integrated platform, we are poised to revolutionize the way sleep apnea is diagnosed and treated.” Ognomy’s patients can see a clinician within days and embark on a personalized treatment plan shortly thereafter, all from the comfort of home. The company has coverage in 43 states and will have full nationwide coverage by the end of 2024. “Sleep apnea is one of the most chronically underdiagnosed and undertreated issues in America, with dire consequences,” said David Brown, partner at Impellent Ventures. “We are excited to support Ognomy as their platform quickly becomes the preeminent way to ensure long-term patient health. Their commitment to improving sleep health through technology has allowed for rapid growth for the company and makes Ognomy well-positioned to have a significant impact on the lives of those suffering from sleep apnea.”